Key result
Adding anti-alpha 2-antiplasmin antibody RWR to t-PA significantly increases in vivo thrombolysis over t-PA alone.
Answers are grounded in this paper and cite their sources.
Recent experiments in vitro have shown that inhibition of human alpha 2-antiplasmin by a monoclonal antibody (MAb RWR) markedly enhances clot lysis by plasminogen activators. To extend these studies in vivo, we tested whether inhibition of clot or fibrin-bound alpha 2-antiplasmin by MAb RWR could enhance the lysis of a human clot by tissue-type plasminogen activator (t-PA) in a rabbit jugular vein thrombosis model. Compared with a saline placebo or a control antibody, MAb RWR significantly increased thrombolysis by endogenous plasminogen activator in rabbits to which no t-PA was administered (p less than 0.05). In rabbits that received t-PA, the combination of MAb RWR and t-PA caused significantly greater thrombolysis than equivalent doses of t-PA alone (p less than 0.05). However, compared with equipotent doses of t-PA alone, the combination of MAb RWR and t-PA did not increase the nonspecific consumption of fibrinogen. These experiments suggest that the combination of an alpha 2-antiplasmin inhibitor and a plasminogen activator could be a more potent thrombolytic strategy.
No takes yet. Share an insight, caveat, or question.
Reed et al. (1990) studied Jugular vein thrombosis (rabbit model with human clot). Monoclonal antibody against alpha 2-antiplasmin (MAb RWR) with or without tissue-type plasminogen activator (t-PA) vs. Saline placebo, control antibody, or equivalent/equipotent doses of t-PA alone was evaluated on Thrombolysis (clot lysis) (p=<0.05). Monoclonal antibody RWR against alpha 2-antiplasmin combined with t-PA increased in vivo thrombolysis compared with equivalent doses of t-PA alone.
Synapse has enriched 10 related papers. Consider them for comparative context: